Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques

AIDS Research and Human Retroviruses

Volumn 27, Issue 9, 2011, Pages 933-943

  Stolte Leeb, Nicole ^a   Loddo, Roberta ^b   Antimisiaris, Sophia ^c   Schultheiss, Tina ^a   Sauermann, Ulrike ^a   Franz, Monika ^a   Mourtas, Spyridon ^c   Parsy, Christophe ^d   Storer, Richard ^d   La Colla, Paolo ^b   Stahl Hennig, Christiane ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF PATRAS   (Greece)

^d Idenix Pharmaceuticals   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MC 1220; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV REVERSE TRANSCRIPTASE; MACACA MULATTA; PYRIMIDINONES; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 79960142180     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0339     Document Type: Article

References (51)

1. Weller S and Davis K: Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;CD003255.
2. de Vincenzi I: A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994;331:341-346. (Pubitemid 24233852)
3. Moscicki AB: Vaginal microbicides: Where are we and where are we going? J Infect Chemother 2008;14:337-341.
4. Brouwers J, Vermeire K, Schols D, and Augustijns P: Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology 2008;378:306-310.
5. Wilson DP, Coplan PM, Wainberg MA, and Blower SM: The paradoxical effects of using antiretroviral-based micro-bicides to control HIV epidemics. Proc Natl Acad Sci USA 2008;105:9835-9840. (Pubitemid 352031386)
6. Abdool KQ, Abdool Karim SS, Fröhlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral micro-bicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
7. Klasse PJ, Shattock RJ, and Moore JP: Which topical micro-bicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006;3:e351.
8. van de Wijgert J and Shattock RJ: Vaginal microbicides: The importance of effective distribution, retention and coating of the mucosa. AIDS 2008;22:1231-1232.
9. Morris GC and Lacey CJ: Microbicides and HIV prevention: Lessons from the past, looking to the future. Curr Opin Infect Dis 2010;23:57-63.
10. Microbicide Development Programme: HIV, prevention gel PRO 2000 proven ineffective. [http:/www.mdp.mrc.ac.uk/accessed 2009 Dec].
11. Galvin SR and Cohen MS: The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004;2:33-42. (Pubitemid 39490046)
12. D'Cruz OJ and Uckun FM: Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006;57:411-423. (Pubitemid 43240192)
13. Balzarini J: Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004;4:921-944. (Pubitemid 38864691)
14. Bartolini S, Mai A, Artico M, Paesano N, Rotili D, Spadafora C, and Sbardella G: 6-[1-(2,6-Difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. J Med Chem 2005;48:6776-6778. (Pubitemid 41533097)
15. Pani A, Musiu C, Loi AG, et al.: DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Che-mother 2001;12 Suppl 1:51-59.
16. Veazey RS, Ketas TA, Klasse PJ, et al.: Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008;105:10531-10536.
17. Grant RM, Hamer D, Hope T, et al.: Whither or wither mi-crobicides? Science 2008;321:532-534.
18. North TW, Van Rompay KK, Higgins J, et al.: Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005;79: 7349-7354. (Pubitemid 40756770)
19. Uberla K, Stahl-Hennig C, Bottiger D, et al.: Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1995;92:8210-8214.
20. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, and Uberla K: Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun 1995;211:850-856.
21. Rosenwirth B, ten Haaft P, Bogers WM, et al.: Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000;74:1704-1711. (Pubitemid 30434026)
22. Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
23. Silvestri R, De Martino G, La Regina G, et al.: Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: Synthesis and SAR studies. J Med Chem 2003;46:2482-2493. (Pubitemid 36637932)
24. D'Cruz OJ, Yiv SH, and Uckun FM: GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS Pharm Sci Tech 2001;2:E5.
25. Wang Y and Lee CH: Characterization of a female controlled drug delivery system for microbicides. Contraception 2002;66:281-287. (Pubitemid 35284537)
26. Stewart JC: Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980;104:10-14. (Pubitemid 10045896)
27. Owen DH, Peters JJ, and Katz DF: Comparison of the rhe-ological properties of Advantage-S and Replens. Contraception 2001;64:393-396. (Pubitemid 34143210)
28. Owen DH, Peters JJ, Lavine ML, and Katz DF: Effect of temperature and pH on contraceptive gel viscosity. Contraception 2003;67:57-64. (Pubitemid 36084290)
29. Marx PA, Spira AI, Gettie A, et al.: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-1089. (Pubitemid 26338626)
30. Suh YS, Park KS, Sauermann U, et al.: Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 2006;24:1811-1820. (Pubitemid 43238262)
31. Negri DR, Baroncelli S, Catone S, et al.: Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 2004;85:1191-1201. (Pubitemid 38659782)
32. Stahl-Hennig C, Voss G, Nick S, et al.: Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology 1992;186:588-596.
33. Garg AB, Nuttall J, and Romano J: The future of HIV mi-crobicides: Challenges and opportunities. Antivir Chem Chemother 2009;19:143-150.
34. Mori K, Yasutomi Y, Sawada S, et al.: Suppression of acute vi-remia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000;74:5747-5753. (Pubitemid 30412940)
35. Van Rompay KK, Johnson JA, Blackwood EJ, et al.: Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 2007;4:25.
36. Münch J, Rucker E, Standker L, et al.: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007;131:1059-1071. (Pubitemid 350235017)
37. VandeVoort CA: High quality sperm for nonhuman primate ART: Production and assessment. Reprod Biol Endocrinol 2004;2:33.
38. Neildez O, Le Grand R, Cheret A, et al.: Variation in viro-logical parameters and antibody responses in macaques after atraumatic vaginal exposure to a pathogenic primary isolate of SIVmac251. Res Virol 1998;149:53-68. (Pubitemid 28162430)
39. Kish-Catalone T, Pal R, Parrish J, et al.: Evaluation of-2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model. AIDS Res Hum Retroviruses 2007;23:33-42. (Pubitemid 46214169)
40. Miller CJ and Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect 2003;5:59-67. (Pubitemid 36197948)
41. Musiu C, Maga G, Spadari S, and La Colla P: Correlation between the virucidal activity of NNRTIs and their binding mode to the HIV-1 RT. Abstracts of the 2nd IAS (International AIDS Society) on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003. Antivir Ther 2003;8(Suppl 1):S187-S557.
42. Caron M, Besson G, Etenna SL, et al.: Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of rhesus macaques with RT-SHIV. Virology 2010;405:225-233.
43. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102. (Pubitemid 41599827)
44. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, and Moore JP: Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005;11:1293-1294. (Pubitemid 41752908)
45. Turville SG, Aravantinou M, Miller T, et al.: Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE 2008;3:e3162.
46. Parikh UM, Dobard C, Sharma S, et al.: Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009;83:10358-10365.
47. Cranage M, Sharpe S, Herrera C, et al.: Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5:e157.
48. Biasin M, Caputo SL, Speciale L, et al.: Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis 2000;182: 1365-1374.
49. Kaul R, Plummer FA, Kimani J, et al.: HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611. (Pubitemid 30067280)
50. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, and Priddy FH: An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt) 2008;17:1025-1034.
51. Grant RM, Lama JR, Anderson PL, et al.: Preexposure che-moprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.